Merit Medical Systems Inc.
MMSI evidence brief
What we can confirm
- BioSniper Score:
- 9.7 / 10
- Market Cap:
- $5.11B
- Lead Asset:
- 5.5 f worley advanced lvi lateral vein introducer
What it means
What to watch
Prepared research question
What matters most for MMSI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MMSI
Merit Medical Systems Inc. (MMSI) is a publicly traded medical device company that designs, manufactures, and distributes products for interventional and diagnostic procedures, with a focus on expanding its global intellectual property portfolio and executing its CGI Program for financial and operating performance.
Key risk: Debt burden
BioSniper Score
Based on 4 of 6 signals
Market Cap
$5.11B
Cash Runway
—
Lead Asset
5.5 f worley advanced lvi lateral vein introducer
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 124 pipeline candidates · 9 clinical trials for Merit Medical Systems Inc..
Merit Medical Systems Inc. (MMSI) is a publicly traded medical device company that designs, manufactures, and distributes products for interventional and diagnostic procedures, with a focus on expanding its global intellectual property portfolio and executing its CGI Program for financial and operating performance.
- Reported revenues of $1.516 billion for the year ended December 31, 2025, representing approximately 7.0% year-over-year constant currency, organic, revenue growth [sec · filed 2026-03-31].
- Non-GAAP operating margin improved by 130 basis points year-over-year for the year ended December 31, 2025 [sec · filed 2026-03-31].
- Free cash flow generation of more than $215 million for the year ended December 31, 2025, up 16% year-over-year [sec · filed 2026-03-31].
- As of June 30, 2026, the company reported cash & equivalents of $448.7M, total revenue of $418.8M, net income of $38.8M, shareholders' equity of $1,679.8M, and total debt of $747.5M [sec].
- Completed acquisitions including C2 CryoBalloon in November 2025, Biolife Merger in May 2025, and assets from Cook Medical Holdings LLC in November 2024 and EndoGastric Solutions, Inc. in July 2024 [sec_mda · as of 2026-04-30].
What works
- The company achieved strong organic revenue growth of approximately 7.0% year-over-year in constant currency for 2025, indicating solid underlying demand for its products [sec · filed 2026-03-31].
- Free cash flow generation increased 16% year-over-year to more than $215 million in 2025, reflecting improved operational efficiency and cash generation [sec · filed 2026-03-31].
- Non-GAAP operating margin improved by 130 basis points year-over-year in 2025, suggesting effective cost management and margin expansion [sec · filed 2026-03-31].
- The company has a substantial shareholders' equity of $1,679.8M as of June 30, 2026, providing a strong financial buffer [sec].
What to weigh
- Total debt of $747.5M as of June 30, 2026, represents a significant financial obligation that could constrain liquidity or business operations [sec].
- The company faces risks from integration of multiple recent acquisitions, including the C2 CryoBalloon and Biolife, which may not achieve anticipated financial results [sec_mda · as of 2026-04-30].
- Forward-looking statements are subject to numerous risks and uncertainties, including supply chain disruptions, regulatory changes, and litigation, which could materially affect actual results [sec_mda · as of 2026-07-30].
From the filings
Quoted directly from source documents.
Revenue growth for 2025
“revenues of $1.516 billion, representing approximately 7.0% year-over-year constant currency, organic, revenue growth”
SEC filings · March 31, 2026
Free cash flow generation for 2025
“free cash flow generation of more than $215 million, up 16% year-over year”
SEC filings · March 31, 2026
Non-GAAP operating margin improvement for 2025
“non-GAAP operating margin year-over-year improvement of 130 basis points”
SEC filings · March 31, 2026
Catalyst timeline
- 2025-02-12 · PDUFA: WRAPSODY Cell-Impermeable Endoprosthesis — The PDUFA date for the WRAPSODY device is a regulatory milestone that could affect product approval and market entry.
Risks & what to watch (3)›
Key risks
- Debt burden — Total debt of $747.5M as of 2026-06-30 may restrict liquidity and business operations [sec].
- Acquisition integration risk — Recent acquisitions may not achieve anticipated financial or operational benefits [sec_mda · as of 2026-04-30].
- Regulatory and legal uncertainties — Changes in regulations, litigation, or product recalls could materially affect results [sec_mda · as of 2026-07-30].
What to watch
- Progress on the CGI Program financial targets for the three-year period ending December 31, 2026 [sec · filed 2026-03-31].
- Integration and financial performance of recent acquisitions, particularly C2 CryoBalloon and Biolife [sec_mda · as of 2026-04-30].
- Development of the next strategic framework and long-range plan as mentioned by CFO Raul Parra [news · published 2026-08-15].
- Outcome of the PDUFA for the WRAPSODY Cell-Impermeable Endoprosthesis, with a catalyst date of 2025-02-12 [catalyst].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Merit Medical Systems Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Merit Medical Systems Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.70 · 1% dilution
Lead: Approved
124 candidates
No upcoming catalysts tracked
5 buys · 3 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 18, 2026- % of float
- 7.3%
- Days to cover
- 5.2
- Shares short
- 3,241,531
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MMSI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Merit Medical Systems Inc.?
Merit Medical Systems Inc. (MMSI) is a publicly traded medical device company that designs, manufactures, and distributes products for interventional and diagnostic procedures, with a focus on expanding its global intellectual property portfolio and executing its CGI Program for financial and operating performance.
Who is the CEO of Merit Medical Systems Inc.?
Ms. Martha Goldberg Aronson is the chief executive officer of Merit Medical Systems Inc. (MMSI).
Where is Merit Medical Systems Inc. headquartered?
Merit Medical Systems Inc. (MMSI) is headquartered in South Jordan, UT, United States.
What therapeutic areas does Merit Medical Systems Inc. focus on?
Merit Medical Systems Inc. develops therapies across Oncology, Cardiovascular, Dermatology, Nephrology, Musculoskeletal, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.